jRCT2080220768未知1 期
A Randomized, Single-Blind, Placebo-Controlled, Multi-Centre, PhaseI Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Treatment, Randomized, Single-Blind(Subject), Parallel Assignment, Safety Study
入排标准
- 年龄范围
- 30age old over 至 75age old under（—）
- 性别
- All
入选标准
- •A body mass index (BMI) of 18 to 27 kg/m
- •Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment.
排除标准
- •Renal dysfunction GFR <60mL/min.
- •Systolic pressure (SBP) >160mmHg or diastolic pressure (DBP) >95mmHg.
- •Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP.
- •History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 study in Patients with Type 2 Diabetes MellitusType 2 Diabetes MellitusEUCTR2012-002414-39-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,202
进行中（未招募）
1 期
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant TherapyEarly-stage non-metastatic breast cancerMedDRA version: 14.1Level: LLTClassification code 10006190Term: Breast cancer invasive NOSSystem Organ Class: 100000004864EUCTR2009-011299-32-NLAmgen Inc4,509
进行中（未招募）
1 期
A clinical trial of Vedolizumab vs. placebo (dummy drug) for the preventionof intestinal Acute Graft Versus Host Disease (aGvHD), in patientsundergoing allo-HSCT for a hematologic malignancy, (cancers that affectthe blood and/or lymphatic system).Intestinal acute graft-versus-host disease (aGvHD)MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersEUCTR2018-002141-11-ATMillennium Pharmaceuticals, Inc.558
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects - BET207MedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityobesityEUCTR2008-001840-38-BEOBEcure180
招募中
1 期
Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingMedDRA version: 20.0Level: PTClassification code: 10013801Term: Duchenne muscular dystrophy Class: 100000004850Duchenne muscular dystrophyCTIS2023-510351-31-00Dyne Therapeutics Inc.75